1 month Seres Therapeutics (NASDAQ:MCRB) Downgraded to Underweight at JPMorgan Chase & Co.MarketBeat
JPMorgan Chase & Co. cut shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday.
XJPMorgan Chase & Co. cut shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday.
X